Rifampicin News and Research RSS Feed - Rifampicin News and Research

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). [More]
LSTM experts use integrated model to assess effects of new diagnostic algorithms for TB

LSTM experts use integrated model to assess effects of new diagnostic algorithms for TB

Experts at LSTM have used a novel modelling approach to project the effects of new diagnostic methods and algorithms for the diagnosis of tuberculosis (TB) recently endorsed by the World Health Organization, looking at the patient, health system and population perspective in Tanzania. [More]
Eating food just before taking TB drug could reduce effectiveness of medicine

Eating food just before taking TB drug could reduce effectiveness of medicine

The timing of food intake in the early phase of TB treatment could have a negative impact on the effectiveness of TB treatment. [More]
First step toward new drugs that can transcend antibiotic resistance issues

First step toward new drugs that can transcend antibiotic resistance issues

Scientists in the United States and India have successfully modified the precursor to one of the drugs used to treat tuberculosis, an important first step toward new drugs that can transcend antibiotic resistance issues that experts consider a serious threat to global health. [More]
New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014. [More]
Otsuka's Deltyba gets EC marketing authorization for MDR-TB treatment

Otsuka's Deltyba gets EC marketing authorization for MDR-TB treatment

Otsuka Pharmaceutical Co., Ltd. today announced that the European Commission has granted a marketing authorization for Deltyba (delamanid) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. [More]
Xpert MTB/RIF test quickly detects TB and resistance to rifampicin

Xpert MTB/RIF test quickly detects TB and resistance to rifampicin

A second systematic review of a diagnostic test for tuberculosis (TB) endorsed by the World Health Organisation (WHO), has confirmed the accuracy of the test. The updated review assessing the accuracy of Xpert MTB/RIF includes new studies published since the original Cochrane Review was published in January last year. [More]
Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)). [More]
Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir. [More]
Groundbreaking study reveals novel approach to treat, eliminate MRSA infection

Groundbreaking study reveals novel approach to treat, eliminate MRSA infection

Recent work from University Distinguished Professor of Biology Kim Lewis promises to overcome one of the leading public health threats of our time. In a groundbreaking study published Wednesday in the journal Nature, Lewis' team presents a novel approach to treat and eliminate methicillin resistant staphylococcus aureus, or MRSA, a potent bacterium whose resistance to antibiotics has kept it one step ahead of researchers. [More]
TB Alliance, Svizera Europe partner to create, enable access to new medicines for childhood TB

TB Alliance, Svizera Europe partner to create, enable access to new medicines for childhood TB

In an effort to develop and deliver treatments for children with tuberculosis—answering a critical need in public health today—TB Alliance, a not-for-profit organization with the mission to develop better, faster-acting, and affordable drugs for TB, has entered into a collaboration with Svizera Europe, one of the leading global supply and distribution companies for TB treatments. [More]
Holistic approach to understand and treat TB

Holistic approach to understand and treat TB

For years, physicians around the world have watched as strain after strain of the deadly bacteria Mycobacterium tuberculosis evolves resistance to drugs. [More]
Vitamin C kills drug-resistant TB bacteria in lab

Vitamin C kills drug-resistant TB bacteria in lab

In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis bacteria in laboratory culture. [More]
Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

MDR-TB is tuberculosis, a mycobacterial infection, that has developed resistance to two important and powerful first-line anti-TB drugs, INH and rifampin. [More]
Tiny proteins prevent bacterial gene transcription

Tiny proteins prevent bacterial gene transcription

In the search for new antibiotics, researchers are taking an unusual approach: They are developing peptides, short chains of protein building blocks that effectively inhibit a key enzyme of bacterial metabolism. [More]

Steroids used for treating TB may reduce death rates from all types of TB

The routine use of steroids to treat tuberculosis may help reduce deaths from all types of the disease, according to a new review of existing research. [More]
Improving tuberculosis (TB) diagnosis: an interview with Professor Madhukar Pai, MD, PhD

Improving tuberculosis (TB) diagnosis: an interview with Professor Madhukar Pai, MD, PhD

TB is an infectious disease caused by Mycobacterium tuberculosis. Nearly 9 million people develop TB every year, and TB kills nearly 1.4 million individuals each year. While the incidence of TB has steadily declined in the west, it remains a huge public health problem in many developing countries, with India having the highest burden. [More]
Xpert diagnosis of TB and its drug resistant strains

Xpert diagnosis of TB and its drug resistant strains

The use of a novel, diagnostic test called Xpert is both sensitive and specific in detecting tuberculosis and rifampicin resistance, report US researchers. [More]

TB test offers rapid detection of TB and drug-resistant strains according to new study

A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library say their study can provide timely advice for clinicians and policymakers in countries where TB is a major public health problem. [More]
High-dose rifampicin combination could improve meningitis survival

High-dose rifampicin combination could improve meningitis survival

A treatment regimen including high-dose rifampicin administered intravenously in addition to standard or high-dose moxifloxacin has an acceptable safety profile and could improve survival for patients with tuberculous meningitis, indicate phase II trial results. [More]